Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 540 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Saying YES: Inspiring a Diverse Generation of Cancer Scientists October 8, 2020 GreaterGood Is Helping UMN Fight Social Injustice with Scholarship for Underrepresented... February 2, 2021 FDA Approves Avapritinib for Advanced Systemic Mastocytosis June 17, 2021 Pink Speed Bump Reminds Drivers to Schedule Their Yearly Mammograms November 1, 2019 Load more HOT NEWS Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and... 105-Year-Old Woman Sets Record For 100-Meter Dash Researchers Create Modified Antibodies to Target RAS and p53 in Cancer
